Structure Therapeutics' Obesity Pill Achieves 16% Weight Loss in Phase 2 Trial
Structure Therapeutics announced a new oral obesity pill that resulted in a 16% weight loss after 44 weeks. This milestone signals a promising competitor to Eli Lilly and Novo Nordisk in the oral GLP-1 treatment market.
· 81d ago
